PHARMION CONFIRMS VIDAZA EUROPEAN REGULATORY STATUS

Pharmion Corporation (Nasdaq: PHRM), as previously announced, confirmed that the European regulatory authorities will require additional data in order to gain marketing approval for Vidaza(R) (azacitidine for injectable suspension) in Europe and today announced the withdrawal of its Marketing Authorization Application (MAA). Pharmion intends to incorporate data from the Company's ongoing survival trial into the MAA.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-17-2005/0004218361&EDATE=)